{"id":"W2618685600","doi":"10.1186/s12933-017-0552-4","title":"Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk","year":2017,"lang":"en","type":"article","venue":"Cardiovascular Diabetology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Medicine; Ezetimibe; Fenofibrate; PCSK9; Internal medicine; Dyslipidemia; Statin; Type 2 diabetes; Endocrinology; Diabetes mellitus; Gastroenterology; Cholesterol; Lipoprotein; Apolipoprotein A1","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02105229,0.003350792,0.004239586,0.0008017974,0.001396745,0.001894088,0.001936088,0.003227164,0.00656624],"category_scores_gemma":[0.01274688,0.001918358,0.002261019,0.0007494239,0.002351952,0.001829784,0.001066553,0.004324446,0.002387774],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001177897,"about_ca_system_score_gemma":0.005644078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006009432,"about_ca_topic_score_gemma":0.001416712,"domain_scores_codex":[0.9880788,0.008744935,0.0005536614,0.00107544,0.0009718535,0.0005754072],"domain_scores_gemma":[0.9968289,0.0008046136,0.0005619235,0.0003324455,0.0004496321,0.001022507],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.8866926,0.008870477,0.01081904,0.007613647,0.002260733,0.000625664,0.0004683537,0.002119161,0.005837708,0.008092598,0.01779797,0.04880198],"study_design_scores_gemma":[0.8954569,0.05066422,0.008762641,0.001315122,0.002763737,0.0003087623,0.0001210195,0.003379576,0.00152639,0.004478772,0.03106228,0.0001605482],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.143571,0.0141584,0.01503503,0.009109019,0.004390413,0.7873452,0.01046165,0.0004341074,0.01549518],"genre_scores_gemma":[0.1763739,0.003008678,0.02493603,0.008489289,0.0014694,0.7781598,0.002645458,0.00006024,0.004857141],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.02105229,"threshold_uncertainty_score":0.1113365,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01652227399736756,"score_gpt":0.2391748565043356,"score_spread":0.222652582506968,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}